Catalent Inc (CTLT)
NYSE NYSE Primary 
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
Catalent Stock Flat Following the Sell Agreement With Ardena
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent , saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalent delays filing of annual report
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
